Cargando…

Association of the RAGE G82S polymorphism with Alzheimer’s disease

The receptor for advanced glycation end-products (RAGE) has been implicated in several pathophysiological processes relevant to Alzheimer’s disease (AD), including transport and synaptotoxicity of AD-associated amyloid β (Aβ) peptides. A recent Chinese study (Li et al. in J Neural Transm 117:97–104,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daborg, Jonny, von Otter, Malin, Sjölander, Annica, Nilsson, Staffan, Minthon, Lennart, Gustafson, Deborah R., Skoog, Ingmar, Blennow, Kaj, Zetterberg, Henrik
Formato:	Texto
Lenguaje:	English
Publicado:	Springer Vienna 2010
Materias:	Dementias - Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895876/ https://www.ncbi.nlm.nih.gov/pubmed/20567859 http://dx.doi.org/10.1007/s00702-010-0437-0

Ejemplares similares

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease
por: Zetterberg, Madeleine, et al.
Publicado: (2010)

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease
por: Andersson, Carl-Henrik, et al.
Publicado: (2016)

Is disrupted sleep a risk factor for Alzheimer’s disease? Evidence from a two-sample Mendelian randomization analysis
por: Anderson, Emma L, et al.
Publicado: (2020)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Ubiquitin Carboxyl-Terminal Esterase LI (UCHLI) SI8Y Polymorphism in Patients with Cataracts
por: Rudolph, Thiemo, et al.
Publicado: (2011)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Association between serum urate and CSF markers of Alzheimer's disease pathology in a population‐based sample of 70‐year‐olds
por: Fatima, Tahzeeb, et al.
Publicado: (2021)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Polygenic risk scores for Alzheimer’s disease, and academic achievement, cognitive and behavioural measures in children from the general population
por: Korologou-Linden, Roxanna, et al.
Publicado: (2019)

Circulating immune complexes of Aβ and IgM in plasma of patients with Alzheimer’s disease
por: Marcello, Andrea, et al.
Publicado: (2009)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

A Western‐style dietary pattern is associated with cerebrospinal fluid biomarker levels for preclinical Alzheimer's disease—A population‐based cross‐sectional study among 70‐year‐olds
por: Samuelsson, Jessica, et al.
Publicado: (2021)

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
por: Voevodskaya, Olga, et al.
Publicado: (2016)

Residential distance from high-voltage overhead power lines and risk of Alzheimer’s dementia and Parkinson’s disease: a population-based case-control study in a metropolitan area of Northern Italy
por: Gervasi, Federico, et al.
Publicado: (2019)

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease
por: Portelius, Erik, et al.
Publicado: (2010)

G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer’s disease pathology
por: C, Rani Cathrine., et al.
Publicado: (2020)

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein
por: Zettergren, Anna, et al.
Publicado: (2019)

A Non-APOE Polygenic Risk Score for Alzheimer’s Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds
por: Skoog, Ingmar, et al.
Publicado: (2021)

Risk of dementia in patients with inflammatory bowel disease: a Danish population‐based study
por: Rønnow Sand, Jakob, et al.
Publicado: (2022)

Correction: G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer’s disease pathology
por: Chellappa, Rani Cathrine, et al.
Publicado: (2021)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study
por: Najar, Jenna, et al.
Publicado: (2021)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Prevalence of preclinical Alzheimer disease: Comparison of current classification systems
por: Kern, Silke, et al.
Publicado: (2018)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

Serum 24‐hydroxycholesterol in probable Alzheimer's dementia: Reexploring the significance of a tentative Alzheimer's disease biomarker
por: Roy, Debashree, et al.
Publicado: (2019)

Advances in screening instruments for Alzheimer's disease
por: Zhou, Xianbo, et al.
Publicado: (2019)

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus
por: Tyrberg, Tobias, et al.
Publicado: (2020)

Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study
por: Eckerström, Marie, et al.
Publicado: (2020)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Reply to “Pathway for ascertaining the role of uric acid in neurodegenerative diseases,” Roman Youssef
por: Dehlin, Mats, et al.
Publicado: (2022)

Low Cerebrospinal Fluid Aβ(42) and Aβ(40) are Related to White Matter Lesions in Cognitively Normal Elderly
por: Skoog, Ingmar, et al.
Publicado: (2018)

Iron and oxidizing species in oxidative stress and Alzheimer's disease
por: Zhao, Zhongwei
Publicado: (2019)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
por: van Westen, Danielle, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_952787jq1m7nl59a4l9aht5plo